HUMAN STUDIES.
ORIGINAL FINDINGS.

298 operators aged 19–38: 148 Bemitil / 150 placebo. Detailed testing: 20-person subset.

The authors report 13.7% greater static-effort endurance, 6.7% shorter simple-reaction latency, half as many complex-reaction errors and 20% fewer complaints in treated sailors.

Limits: These are reported changes in treated sailors, not calculated placebo-adjusted effects. Subset allocation, randomization and blinding are not described. Morbidity percentages lack clear denominators. Allergic reactions (2%), reduced appetite (2.7%) and nausea (0.7%) are reported without separately tabulated denominators.

Material reviewed: Original Russian journal scan, pp. 37–39 and Tables 1–2, checked October 29, 2026.

Human operators in simulated spaceflight and sustained-work conditions.

Compared with placebo, the abstract reports 10% better compensatory tracking, 1.8-fold fewer pursuit-tracking errors and 2.4-fold shorter visual-signal detection time.

Limits: Task-specific historical results. Sample size, allocation method and detailed masking procedures are absent from the indexed abstract.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Human heat/exertion comparisons. A companion report specifies volunteers at 30 ± 1°C with physical loading and protective equipment.

The reports describe thermal-tolerance and work-capacity effects for the tested agents. The first favors phenibut; the companion report favors phenibut plus propranolol.

Limits: No Bemitil-specific numerical benefit can be extracted from these abstracts. Similar authors and settings may overlap. Two reports do not establish two independent replications.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

78 healthy adults aged 18–25 across eight groups, including placebo, two Bemitil arms and a piracetam–Bemitil combination.

Table 39 reports dynamic-endurance retention of 86.2% of baseline in one Bemitil arm versus 68.1% with placebo (p<0.05). Table 40 reports a dynamic-recovery index of 1.50 versus 1.00 in another Bemitil arm (p<0.01).

Limits: The chapter describes double blinding but gives no group-specific n or random-allocation procedure in the reviewed section. These are different arms and endpoints. Recovery-index ratios do not mean recovery was 50% faster. Publication year identifies the book, not the experiment date. No controlled heat exposure is described.

Material reviewed: Recovered monograph Work Capacity, Fatigue, Correction (2019), section 6.2, pp. 184–189; narrative and Tables 39–40 checked.

Separate series of 20 physically trained men, described as double blind with placebo and at least ten days between treatment periods.

The narrative reports Bemitil-associated mean reductions of 30 seconds over 6 km and 82 seconds over 10 km. Sydnocarb showed larger reductions.

Limits: The reported passage supplies no Bemitil-specific uncertainty or p-value and no raw placebo running times. Randomized sequence is not described. This is a book-reported series, not a newly verified standalone trial.

Material reviewed: Same 2019 monograph, pp. 189–190; separate series from the 78-volunteer comparison.

130 patients with asthenic conditions associated with neuropsychiatric disturbances. Active comparators: piracetam and pyritinol.

The authors report earlier and greater improvement in asthenic symptoms with Bemitil.

Limits: No placebo arm, numerical effect size, randomization or masking is established in the abstract. Treatment schedules evolved during the study. Patient findings do not establish benefit in healthy workers.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Patients with persistent asthenic symptoms after moderate isolated brain injury.

Combined bemithyl and pyrazidol treatment reportedly reduced asthenic symptoms and changed oxidative-stress measures.

Limits: Combination treatment cannot isolate Bemitil’s contribution. The abstract omits sample size, detailed allocation and a numerical clinical effect.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

A 66-patient report compares conventional care plus Bemitil with conventional care plus placebo. A related report examines immune measures.

The 66-patient abstract reports earlier symptom resolution and discharge. The related publication describes changes in T cells and immunoglobulins.

Limits: Randomization, masking and numerical time differences are not supplied. Cohort overlap between the two publications is unresolved. These infection-treatment reports do not establish fatigue efficacy.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

51 men aged 20–30 with skin infection; Bemitil-containing treatment compared with conventional care.

The abstract reports clinical recovery in 86.3 ± 4.8% versus 62.1 ± 6.8% with conventional treatment.

Limits: Group sizes, allocation, masking and the meaning of the ± values are not established. Systemic, local and combined use complicate attribution. Recovery from skin infection is not a performance or heat-tolerance endpoint.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Four treatment groups of 15–16 patients, assessed over eight weeks.

Bemitil-containing regimens reportedly reduced anti-DNA antibodies and disease-activity scores.

Limits: Background and combination treatments differ. Randomization, masking and numerical score changes are absent from the abstract. This supplies clinical context, not a validated Antaeus indication.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Healthy adult volunteers receiving oral Metaprot.

Mean time to peak concentration was 1.06 ± 0.16 hours, with substantial exposure variability and a multimodal distribution.

Limits: Sample size and full methods require review. Pharmacokinetics do not establish performance efficacy or a complete safety profile.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Six adults: three women and three men aged 26–49.

Urine analysis detected Bemitil and its glucuronide conjugate. The conjugate provided a wider detection window.

Limits: This analytical study measured detection, not exercise performance, treatment benefit or a safe regimen. Background efficacy statements in its introduction are not results from these six volunteers.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Clinical pharmacokinetic studies in patients with asthenic or asthenoneurotic disturbances.

The reports associate kinetic differences with clinical responses and describe correlations between test-dose parameters and therapeutic effect.

Limits: Small-study methods and cohort independence require full-text appraisal. The 1991 report includes monotherapy and phenazepam combinations. Correlation does not establish efficacy or predict outcomes in healthy operators.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Volunteers moving from 1,670 m to 3,750 m after 15 days at middle altitude.

Metaprot plus Ladasten reportedly improved exercise tolerance and accelerated selected adaptation measures compared with placebo and hypoxen.

Limits: No single-component arms are described, so Bemitil’s contribution and synergy cannot be established. Enrollment, allocation and masking require the full paper.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Volunteers; placebo, Bemitil, bromantane and combination arms.

The abstract favors bromantane alone or its combination with Bemitil.

Limits: The title says carbon monoxide while the English abstract says carbon dioxide. The original methods must resolve the gas identity. Sample size, allocation and quantitative effects are not supplied.

Material reviewed: Indexed abstract reviewed; full methods not appraised.

Historical human exposure report.

The abstract describes improved resistance under combined heat and carbon-oxide exposure.

Limits: The apparent dose-unit error requires the original text. No exposure-protection percentage or dosing guidance is inferred. These reports do not establish that hazardous exposure is safe.

Material reviewed: Indexed abstract reviewed; full methods not appraised.